Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06672692 · ClinicalTrials.gov registry record · NA

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

A NA study of COVID-19 and Influenza a, sponsored by DiaSorin Molecular.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
3
Study locations

NCT06672692 is a NA study of COVID-19 and Influenza a that is actively recruiting participants, run by DiaSorin Molecular. The registered enrollment target is 1,000 participants, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06672692, a NA study of COVID-19 and Influenza a, is actively recruiting participants, sponsored by DiaSorin Molecular.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
3
Study locations

Study Summary

The DiaSorin Molecular LIAISON® NES FLU A/B, RSV \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. The LIAISON® NES FLU A/B, RSV \& COVID-19 assay is intended for use as an aid in the differential diagnosis of influenza A, influenza B, RSV and SARS-CoV-2 infection in a professional laboratory setting. Negative results do not preclude influenza A, influenza B, RSV or SARS-CoV-2, infection and should not be used as the sole basis for patient management decisions. The assay is not intended to detect the presence of the influenza C virus.

Conditions Studied

COVID-19 Influenza a Influenza B RSV

Interventions

  • DIAGNOSTIC_TEST LIAISON NES FLU A/B, RSV & COVID-19

Study Locations (3)

Nevada

  • PAS Research - Henderson - Henderson

Pennsylvania

  • PAS Research - Pittsburgh - Pittsburgh

Texas

  • PAS Research - McAllen - McAllen

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-09-30
Est. Completion 2025-05
Phase NA

Sponsor

DiaSorin Molecular

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06672692

The ClinicalTrials.gov registry entry for NCT06672692 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is DiaSorin Molecular, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which LIAISON NES FLU A/B, RSV & COVID-19 is the first listed.

NCT06672692 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nevada, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT06672692 about?

NCT06672692 is a clinical study titled "A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients". The DiaSorin Molecular LIAISON® NES FLU A/B, RSV \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 vir...

What is the current status of trial NCT06672692?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-09-30. Estimated completion is 2025-05.

What conditions does trial NCT06672692 study?

This clinical trial studies the following conditions: COVID-19, Influenza a, Influenza B, RSV.

What interventions are being tested in trial NCT06672692?

The interventions under investigation include: LIAISON NES FLU A/B, RSV & COVID-19 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06672692?

This trial is sponsored by DiaSorin Molecular, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06672692 being conducted?

This trial has 3 study locations across Nevada, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Influenza a

All registered trials for this condition

Nevada

All trials with a study site in Nevada

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.